Sanofi Aventis Pakistan

What Sanofi Aventis Pakistan does

Sanofi Aventis Pakistan is the Pakistani operating subsidiary of Sanofi S.A., a global R&D-driven biopharmaceutical company. The subsidiary, headquartered in Karachi and operating since 1967, is part of the Sanofi group formed through the 2004 merger of Sanofi-Synthélabo and Aventis. It participates in the global Sanofi portfolio spanning five therapeutic areas: Immunology, Neurology, Oncology, Rare Diseases, and Vaccines.

The underlying technology platform is centered on AI-powered biopharmaceutical R&D, with dedicated digital and AI capabilities applied across research, manufacturing, and patient engagement. The global pipeline comprises 77 compounds in clinical development, including 21 Phase 3 trials, with recent approvals including Cenrifki (tolebrutinib) in the EU for secondary progressive multiple sclerosis and Wayrilz in Japan for immune thrombocytopenia. The consumer healthcare business operates under the Opella sub-brand.

The business model combines prescription pharmaceutical sales through healthcare providers, hospital systems, and government health programs with consumer healthcare distribution via retail pharmacies. Revenue is generated through product sales across therapeutic franchises globally, though specific revenue, pricing, and customer-level data for the Pakistan subsidiary are not disclosed in the available material.

Name

Sanofi Aventis Pakistan

Legal name

Sanofi S.A.

Website

https://sanofi.com.pk

Company type

Public

Founded year

2004

Operating status

Operating

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)

Keywords

• Pharmaceutical manufacturing
• Prescription medicines
• Vaccines production
• Consumer healthcare
• Biopharmaceutical products

Headquarters

HQ city

Karachi

HQ country

Pakistan

HQ region

Asia

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Distribution channels3 records

Marketing channels5 records

Core offering

Sanofi Aventis Pakistan is a bio-pharmaceutical company that develops, manufactures, and distributes prescription medicines, vaccines, and consumer healthcare products in Pakistan. The company operates across five therapeutic areas: Immunology, Neurology, Oncology, Rare Diseases, and Vaccines, leveraging AI-powered research and development to deliver breakthrough therapies to patients.

Product overview

Sanofi is an R&D-driven, AI-powered biopharmaceutical company operating across five core therapeutic areas: Immunology, Neurology, Oncology, Rare Diseases, and Vaccines. The company develops breakthrough medicines and vaccines with a pipeline of 77 compounds in clinical development, including 21 clinical trials in phase 3. Key products include Wayrilz (approved in Japan for immune thrombocytopenia) and Cenrifki/tolebrutinib (approved in EU for secondary progressive multiple sclerosis). The consumer healthcare division operates under the Opella brand. The company positions itself as AI-powered, utilizing artificial intelligence across its R&D operations.

Differentiator

Problem solved

Functional benefit

Brands

• Opella: Consumer Healthcare division of Sanofi

Products and services

• Wayrilz Drug approved for the treatment of immune thrombocytopenia (ITP), an immunological condition, marketed to healthcare providers and patients.
• Cenrifki (tolebrutinib) First disability-targeting medicine for secondary progressive multiple sclerosis without relapses, approved in the EU, targeting neurological patients.
• Opella Consumer Healthcare Consumer healthcare division offering over-the-counter medicines and health products distributed through retail pharmacies and stores for individual consumers.

Quantifiable outcome

• 77 compounds in clinical development
• +3 more outcomes

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• STATION FcoreStrategic or Co-development PartnerSanofi x STATION F partnership focused on startups and innovation ecosystem. The collaboration provides a platform for innovative healthcare startups to access Sanofi's resources and expertise in biopharmaceutical development.
• China PartnerscoreStrategic or Co-development PartnerStrategic partnering focus area for China market, including external innovation initiatives in China focused on R&D collaboration and market development.
• Digital PartnerscoreTechnology or IntegrationDigital partnering focus area for technology collaborations, AI integration, and digital health solutions development.
• Out-Licensing PartnersminorOEM/ Whitelabel/ Licensing PartnerOut-licensing partnerships for technology platforms, intellectual property, and pipeline assets to other pharmaceutical companies.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• AstraZeneca: AstraZeneca is a global biopharmaceutical company with a major focus on oncology, rare diseases, and immunology. It is a direct pipeline and commercial competitor in several of Sanofi's strategic therapeutic areas.
• AbbVie: AbbVie is a global biopharmaceutical company with a leading immunology franchise (Humira/Skyrizi/Rinvoq) that competes directly with Sanofi's immunology portfolio, and it also operates in oncology and neuroscience.
• Roche: Roche is a global pharmaceutical and diagnostics company with major franchises in oncology, immunology, and neurology. It is one of the closest competitors to Sanofi in oncology and immunology R&D and global commercialization.
• Merck & Co. Merck is a global biopharmaceutical company with leading franchises in oncology, vaccines, and animal health. It directly competes with Sanofi across vaccines and oncology pipelines and shares a comparable global commercialization footprint.
• Johnson & Johnson (Innovative Medicine): Johnson & Johnson's Innovative Medicine division competes with Sanofi across immunology, oncology, and neuroscience, with comparable pipeline depth and global commercialization scale.
• Novartis: Novartis is a Swiss-headquartered global pharmaceutical company focused on innovative medicines across immunology, neuroscience, oncology, and rare diseases. Its therapeutic portfolio and pipeline depth are directly comparable to Sanofi's strategic focus areas.
• Bristol-Myers Squibb: Bristol-Myers Squibb is a US-headquartered global biopharmaceutical company with strong positions in oncology, immunology, and cardiovascular disease. Its strategic therapeutic areas overlap substantially with Sanofi's.
• GSK (GlaxoSmithKline): GSK is a UK-headquartered global pharmaceutical and vaccines company. It competes most directly with Sanofi's vaccines business and overlapping immunology and rare disease programs, and shares a similar European public-company governance profile.
• Eli Lilly: Eli Lilly is a global pharmaceutical company with major franchises in immunology, oncology, neuroscience, and diabetes. It is a leading direct competitor to Sanofi in immunology and metabolic disease research.
• Pfizer: Pfizer is a global biopharmaceutical company with overlapping therapeutic areas including oncology, vaccines, immunology, and rare diseases. Both companies operate large late-stage pipelines, pursue first-in-class approvals, and compete for the same global payer and provider relationships.

Market position

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/sanofi
• Facebookfacebook.com/Sanofi
• LinkedInlinkedin.com/company/sanofi
• Instagraminstagram.com/sanofi

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sanofi Aventis Pakistan